| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/23/2009 | US20090105687 Scoring catheter with drug delivery membrane |
| 04/23/2009 | US20090105460 Antibody and inhibitor, and transfection method or kit using them |
| 04/23/2009 | US20090105150 Angiotensin derivatives |
| 04/23/2009 | US20090105131 Use of poly-alpha2,8-sialic acid mimetic peptides to modulate ncam functions |
| 04/23/2009 | US20090105086 Methods of selecting internalizing antibodies |
| 04/23/2009 | US20090104684 Diagnosis of carcinomas |
| 04/23/2009 | US20090104662 Use of interleukin-4 antagonists and compositions thereof |
| 04/23/2009 | US20090104631 Psca: prostate stem cell antigen and uses thereof |
| 04/23/2009 | US20090104618 Diagnosing high grade ductal carcinoma (mammary glands) in situ (DCIS) by determining the level of psoriasin gene expression in a sample |
| 04/23/2009 | US20090104271 Use of microparticles combined with submicron oil-in-water emulsions |
| 04/23/2009 | US20090104268 Nanoparticles Comprising Antigens and Adjuvants, and Immunogenic Structures |
| 04/23/2009 | US20090104260 Compositions and methods for sirna inhibition of icam-1 |
| 04/23/2009 | US20090104259 Compositions and methods for sirna inhibition of angiogenesis |
| 04/23/2009 | US20090104234 Methods of treating chronic neurogenic inflammation using modified clostridial toxins |
| 04/23/2009 | US20090104233 IDENTIFICATION OF RESIDUES CRITICAL FOR THE FUNCTION OF THE VIBRIO CHOLERAE VIRULENCE REGULATOR ToxT BY SCANNING ALANINE MUTAGENESIS |
| 04/23/2009 | US20090104232 Yersina virulence antigen specific monoclonal antibody for use in prevention of plague; prevention of bioterrorism; directed protein evolution |
| 04/23/2009 | US20090104231 Vaccine |
| 04/23/2009 | US20090104230 Compositions and methods of using capsid protein from flaviviruses and pestiviruses |
| 04/23/2009 | US20090104229 Novel use |
| 04/23/2009 | US20090104228 Influenza Virus Vaccine |
| 04/23/2009 | US20090104227 Vaccine composition for the prevention of cmv infection |
| 04/23/2009 | US20090104226 Alphavirus Vectors for Respiratory Pathogen Vaccines |
| 04/23/2009 | US20090104225 using recombinant modified vaccinia virus Ankara (MVA) encoding a polypeptide comprising a human prostate-specific antigen (PSA) antigen and another encoding prostatic acid phosphatase (PAP); can induce B- and T-cell responses |
| 04/23/2009 | US20090104224 Modified vaccinia virus ankara for the vaccination of neonates |
| 04/23/2009 | US20090104223 Method for Obtaining Antigenic Aggregates and the Use Thereof in Formulations |
| 04/23/2009 | US20090104221 Rapid generation of t cell-independent antibody responses to t cell-dependent antigens |
| 04/23/2009 | US20090104220 Method to Make a Peptide-Carrier Conjugate with a High Immunogenicity |
| 04/23/2009 | US20090104219 Antigenic polypeptide SE36 of malaria plasmodium, process for purification thereof, and vaccine and diagnostic agent using the antigen |
| 04/23/2009 | US20090104218 Group B Streptococcus |
| 04/23/2009 | US20090104217 Pharmaceutical Composition Comprising An Antigen |
| 04/23/2009 | US20090104216 Peptide-Based Influenza Vaccine Formulation |
| 04/23/2009 | US20090104215 Methods and compositions for modulating tumor cell activity |
| 04/23/2009 | US20090104214 Synthetic peptides containing the motif "YWWLXP" as anthrax toxin antidotes |
| 04/23/2009 | US20090104213 Vaccine for House Dust Mite Allergen Using Naked DNA |
| 04/23/2009 | US20090104212 Methods and systems for treating cell proliferation disorders using two-photon simultaneous absorption |
| 04/23/2009 | US20090104211 Treatment of atherosclerosis |
| 04/23/2009 | US20090104210 Peptide compounds for treating obesity and insulin resistance |
| 04/23/2009 | US20090104209 Methods of reducing a viral infection and kits therefore |
| 04/23/2009 | US20090104208 House Dust Mite Allergen |
| 04/23/2009 | US20090104207 Hepatitis C Virus Neutralizing Antibodies |
| 04/23/2009 | US20090104206 Bone microenvironment modulated migraine treatments |
| 04/23/2009 | US20090104205 Human-Murine Chimeric Antibodies Against Respiratory Syncytial Virus |
| 04/23/2009 | US20090104204 Human Binding Molecules Having Killing Activity Against Staphylococci and Uses Thereof |
| 04/23/2009 | US20090104203 Compositions and Methods for Regulating Osteoclast Differentiation, Activation and Bone Resorption |
| 04/23/2009 | US20090104202 CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases |
| 04/23/2009 | US20090104201 Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis |
| 04/23/2009 | US20090104200 Modulating inflammasome activity and inflammation in the central nervous system |
| 04/23/2009 | US20090104199 Breast Cancer Resistance Protein (BCRP) And The DNA Which Encodes It |
| 04/23/2009 | US20090104198 Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof |
| 04/23/2009 | US20090104197 vWFA and/or ANT_IG Domain Containing Proteins |
| 04/23/2009 | US20090104196 for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal; for identifying a patient having high risk prostate carcinomas |
| 04/23/2009 | US20090104195 Targeted ligands |
| 04/23/2009 | US20090104194 Bi-directional antibody for treatment of ocular disorders |
| 04/23/2009 | US20090104193 SEMA4D in Cancer Diagnosis, Detection and Treatment |
| 04/23/2009 | US20090104192 Monoclonal Antibodies to Hepatocyte Growth Factor |
| 04/23/2009 | US20090104191 Prevention of tumors with monoclonal antibodies against neu |
| 04/23/2009 | US20090104190 Humanized anti-cd4 antibody with immunosuppressive properties |
| 04/23/2009 | US20090104189 Neutrokine-alpha and neutrokine-alpha splice variant |
| 04/23/2009 | US20090104188 Anti-hepatitis c virus antibody and uses thereof |
| 04/23/2009 | US20090104187 Novel Rabbit Antibody Humanization Methods and Humanized Rabbit Antibodies |
| 04/23/2009 | US20090104186 Melanoma-associated MHC class I associated oligopeptides and the uses thereof |
| 04/23/2009 | US20090104185 Methods and Compositions for Mycoplasma Toxins |
| 04/23/2009 | US20090104184 Pharmaceutical compositions containing monoclonal anti idiotypic anti-CA-125 antibody and aluminium |
| 04/23/2009 | US20090104183 Glue composition for lung volume reduction |
| 04/23/2009 | US20090104182 Inhibition of tristetraproline for protection of the heart from cardiac injuries |
| 04/23/2009 | US20090104181 Antibodies for Discrimination of Prions |
| 04/23/2009 | US20090104180 Using selectin/immunoglobulin fusion for quelling organ transplant rejection |
| 04/23/2009 | US20090104179 Ionizing-radiation-responsive compositions, methods, and systems |
| 04/23/2009 | US20090104178 Chemokine binding activity of viral tnf receptors and related proteins |
| 04/23/2009 | US20090104177 Peptides for inhibiting the interaction of protein kinase a and protein kinase a anchor proteins |
| 04/23/2009 | US20090104151 Smac mimetic dimers and trimers useful as anti-cancer agents |
| 04/23/2009 | US20090104150 Polymer conjugates of interferon Beta-1a and uses |
| 04/23/2009 | US20090104148 Treatment and prevention of joint disease |
| 04/23/2009 | US20090104147 Sialoadhesin-Related Compositions and Methods |
| 04/23/2009 | US20090104121 Multi-subunit biological complexes for treatment of plaque-associated diseases |
| 04/23/2009 | US20090104119 Dendrimer Based Compositions And Methods Of Using The Same |
| 04/23/2009 | US20090104117 Compositions and methods of use of targeting peptides against placenta and adipose tissues |
| 04/23/2009 | US20090104115 Cancerous disease modifying antibodies |
| 04/23/2009 | US20090104114 Nanotherapeutic Colloidal Metal Compositions and Methods |
| 04/23/2009 | CA2740882A1 Use of ps20/wfdc1 and interferons to diagnose, monitor and treat viral diseases |
| 04/23/2009 | CA2734173A1 Igm-mediated receptor clustering and cell modulation |
| 04/23/2009 | CA2709679A1 Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes |
| 04/23/2009 | CA2703720A1 Improved antitumoral treatments |
| 04/23/2009 | CA2703050A1 Anti-amyloid antibodies, compositions, methods and uses |
| 04/23/2009 | CA2703034A1 Viral modification |
| 04/23/2009 | CA2702939A1 Anti-bst2 antibody |
| 04/23/2009 | CA2702880A1 Antibody capable of specifically binding to a beta oligomer, and use thereof |
| 04/23/2009 | CA2702871A1 Meningococcal vaccine formulations |
| 04/23/2009 | CA2702617A1 Immunotherapy regimes dependent on apoe status |
| 04/23/2009 | CA2702586A1 Use of mva to treat prostate cancer |
| 04/23/2009 | CA2702572A1 Tr1 cells, mesenchymal stem cells and uses thereof |
| 04/23/2009 | CA2702555A1 Cd19 binding agents and uses thereof |
| 04/23/2009 | CA2702494A1 Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss |
| 04/23/2009 | CA2702473A1 Antibodies that bind il-4 and/or il-13 and their uses |
| 04/23/2009 | CA2702300A1 Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent |
| 04/23/2009 | CA2702083A1 Vaccine nanotechnology |
| 04/23/2009 | CA2701329A1 Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease |
| 04/23/2009 | CA2700288A1 Method for producing flu virus |
| 04/23/2009 | CA2700168A1 Patch with hydrophilic adhesive |
| 04/22/2009 | EP2051079A2 Annexins as markers for lung or esophageal cancer |